Knowing the primary site of metastatic cancer helps determine treatment. Doctors perform clinical and imaging testing to diagnose most cancers. However, some cancers are difficult to diagnose, and pathologists cannot identify the primary sites of around 5% of cancers. This means around 30,000 people are diagnosed with cancer of unknown primary (CUP) each year. Being able to accurately predict where a CUP started may also help identify a targeted drug that could be beneficial. For example, if a CUP is thought to have started in the lung, it may respond to a targeted therapy currently approved for lung cancer.
We build machine learning models using a wealth of cancer data. Our models are able to identify the primary site of tumor samples with high sensitivity and specificity. Not only can we identify the tumor's original tissue, but we use these models to diagnose subtypes as well.
Our lab is CLIA Registered. We are preparing to go commercial with CUPid℠ as soon as we obtain our CLIA Certification this summer. In the meantime, CUPid℠ is for research use only. If you would like more information or are interested in ordering, please fill out the contact form and we will reach out to you.
Rapidly produces a perpetual supply primary cancer cells from a variety of patient tumor specimens.
Store your original tumor or amplified tumor cells in an account that never runs out of living tumor cells.